These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1048 related articles for article (PubMed ID: 20945361)
1. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery. Matta A; Ralhan R; DeSouza LV; Siu KW Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361 [TBL] [Abstract][Full Text] [Related]
2. Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery. Fang X; Balgley BM; Lee CS Electrophoresis; 2009 Dec; 30(23):3998-4007. PubMed ID: 19960464 [TBL] [Abstract][Full Text] [Related]
3. The proteomic advantage: label-free quantification of proteins expressed in bovine milk during experimentally induced coliform mastitis. Boehmer JL; DeGrasse JA; McFarland MA; Tall EA; Shefcheck KJ; Ward JL; Bannerman DD Vet Immunol Immunopathol; 2010 Dec; 138(4):252-66. PubMed ID: 21067814 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. Matta A; DeSouza LV; Shukla NK; Gupta SD; Ralhan R; Siu KW J Proteome Res; 2008 May; 7(5):2078-87. PubMed ID: 18407684 [TBL] [Abstract][Full Text] [Related]
5. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. Bouchal P; Roumeliotis T; Hrstka R; Nenutil R; Vojtesek B; Garbis SD J Proteome Res; 2009 Jan; 8(1):362-73. PubMed ID: 19053527 [TBL] [Abstract][Full Text] [Related]
6. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy. Fredolini C; Liotta LA; Petricoin EF Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067 [TBL] [Abstract][Full Text] [Related]
7. Cancer proteomics: from biomarker discovery to signal pathway profiling. Bichsel VE; Liotta LA; Petricoin EF Cancer J; 2001; 7(1):69-78. PubMed ID: 11269650 [TBL] [Abstract][Full Text] [Related]
8. Head and neck cancer: proteomic advances and biomarker achievements. Rezende TM; de Souza Freire M; Franco OL Cancer; 2010 Nov; 116(21):4914-25. PubMed ID: 20665484 [TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
10. Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view? Kraljevic S; Sedic M; Scott M; Gehrig P; Schlapbach R; Pavelic K Cancer Treat Rev; 2006 Dec; 32(8):619-29. PubMed ID: 17069979 [TBL] [Abstract][Full Text] [Related]
11. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Bharti A; Ma PC; Salgia R Mass Spectrom Rev; 2007; 26(3):451-66. PubMed ID: 17407130 [TBL] [Abstract][Full Text] [Related]
12. Pre-analytic saliva processing affect proteomic results and biomarker screening of head and neck squamous carcinoma. Ohshiro K; Rosenthal DI; Koomen JM; Streckfus CF; Chambers M; Kobayashi R; El-Naggar AK Int J Oncol; 2007 Mar; 30(3):743-9. PubMed ID: 17273777 [TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of protein expression in human tonsillar cancer: differentially expressed proteins characterize human tonsillar cancer. Roblick UJ; Bader FG; Hammarstedt L; Habermann JK; Hellman U; Becker S; Sundmacker A; Gemoll T; Zimmermann K; Auer G; Munck-Wikland E Acta Oncol; 2008; 47(8):1493-501. PubMed ID: 18759147 [TBL] [Abstract][Full Text] [Related]
14. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery. Hu S; Yen Y; Ann D; Wong DT Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408 [TBL] [Abstract][Full Text] [Related]
15. Identification of proteins secreted by head and neck cancer cell lines using LC-MS/MS: Strategy for discovery of candidate serological biomarkers. Ralhan R; Masui O; Desouza LV; Matta A; Macha M; Siu KW Proteomics; 2011 Jun; 11(12):2363-76. PubMed ID: 21598386 [TBL] [Abstract][Full Text] [Related]
16. Advanced proteomic technologies for cancer biomarker discovery. Wong SC; Chan CM; Ma BB; Lam MY; Choi GC; Au TC; Chan AS; Chan AT Expert Rev Proteomics; 2009 Apr; 6(2):123-34. PubMed ID: 19385940 [TBL] [Abstract][Full Text] [Related]
17. Proteomics for the identification of new prostate cancer biomarkers. Ornstein DK; Tyson DR Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055 [TBL] [Abstract][Full Text] [Related]
18. Proteomics in prostate cancer biomarker discovery. Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479 [TBL] [Abstract][Full Text] [Related]
19. [Novel tumor marker discovery of gastrointestinal cancers using various proteomic approaches]. Tomonaga T; Nomura F Rinsho Byori; 2007 Jan; 55(1):63-8. PubMed ID: 17319493 [TBL] [Abstract][Full Text] [Related]
20. Recent advances in clinical proteomics using mass spectrometry. Dowling P; Meleady P; Henry M; Clynes M Bioanalysis; 2010 Sep; 2(9):1609-15. PubMed ID: 21083289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]